# Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinoma of the Esophagogastric Junction Who Underwent Radical Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy and Achieved pCR in Postoperative Pathology

> **NCT07161453** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Liaoning Cancer Hospital & Institute** · enrollment: 500 (estimated)

## Conditions studied

- Gastric / Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** SOX plus PD-1 inhibitor
- **DRUG:** PD-1 / PD-L1 monoclonal antibody
- **DRUG:** SOX Chemotherapy
- **DRUG:** Tegafur-Ugotex or Capecitabine

## Key facts

- **NCT ID:** NCT07161453
- **Lead sponsor:** Liaoning Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-30
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2025-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07161453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07161453, "Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinoma of the Esophagogastric Junction Who Underwent Radical Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy and Achieved pCR in Postoperative Pathology". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07161453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*